While Merck’s product sales and financial performance have been less than impressive of late, the company’s pipeline is providing hope for the future.
Novartis has undergone a series of transactions that now concentrate the company on three leading divisions with innovation power and worldwide scale: pharmaceuticals, eye care and generics.
With new CEO Olivier Brandicourt at the helm, launches of new products in 2014 and 2015, pipeline progression, R&D collaborations and the reorganization of the company into a new structure coming in 2016, Sanofi is setting the stage for the future.
By Arun Ramesh, Lead Analyst, Beroe Inc. Abstract 1 Serialization – Need of the HourLack of global co-operation on agreement with one common technology over the years has delayed […]
The big worries on growth hanging over the pharmaceuticals industry are poles apart. Pressure on U.S. drug pricing is casting a shadow over the sector’s most lucrative market. But slowing […]
SHYFT Analytics Delivers Transformational Insights to Life Sciences With Next Generation Real World Evidence Analytics Platform WALTHAM, MA–(Marketwired – Jul 29, 2015) – SHYFT Analytics, a leader in cloud-based data […]
Paul Allen, philanthropist and co-founder of Microsoft, has devoted many millions of dollars to unlocking the mysteries of the brain, and today he’s taking on a new challenge: Alzheimer’s disease. […]
Just when you think a biotech bear market is about to descend, the bulls come rushing in. News of a Greek default depressed markets yesterday and was only compounded by fears […]
